Effectiveness and safety of olanzapine in the treatment of Asian outpatients with schizophrenia
Document Type
Article
Publication Date
1-1-2007
Abstract
Objective: The objective of this study was to assess the effectiveness and safety of olanzapine in the treatment of schizophrenia among Asian patients in an outpatient setting. Methods: This was an open-label, prospective, observational study involving 339 patients from Indonesia, Pakistan, Malaysia, Thailand, and Singapore. Brief Psychiatric Rating Scale (BPRS), Clinical Global Impression Severity scale (CGI-S), and safety parameters were assessed. Results: 62 of patients responded to olanzapine treatment, defined a priori as a reduction in BPRS of > 40 from baseline. Following the 8-week treatment period, the BPRS total, BPRS positive, BPRS negative, and CGI-S scores decreased by 18.7 (95 CT: 17.4 20.2), 6.1 (5.6, 6.6), 2.9 (2.6, 3.2), and 1.5 points (median 1.0), respectively (p < 0,0001). In total, 31 of the 339 patients (9.1) failed to complete the study according to the study description. Loss to follow-up and personal conflict were the most common reasons for discontinuation. There were 30 treatment-emergent adverse events with six serious cases, assessed as unrelated to study drug, reported. Conclusion: This study further demonstrates the effectiveness and safety of olanzapine in actual clinical practice settings, in reducing the severity of psychopathological symptoms in Asian patients with schizophrenia.
Keywords
Olanzapine, schizophrenia, Asian patients, observational study, safety, atypical antipsychotic olanzapine, double-blind
Divisions
fac_med
Publication Title
International Journal of Clinical Pharmacology and Therapeutics
Volume
45
Issue
12